Key Takeaways
- Medicinrådet has expanded the recommendation for risdiplam, making it accessible to SMA patients of all ages, including those over 25, following a new pricing agreement with Roche that balances cost with expected treatment benefits.
- The expansion of risdiplam use to older adults is a significant advancement in SMA treatment, providing a non-invasive, oral therapy option that can be administered at home, unlike other treatments that require more invasive procedures.
- While the broader recommendation for risdiplam has been welcomed by patient advocacy groups, it also underscores the ongoing challenge of ensuring equitable and sustainable access to new and expensive therapies for rare diseases like SMA.
In a pivotal move that broadens access to treatment for spinal muscular atrophy (SMA), the Danish Medicines Council (Medicinrådet) has officially extended its recommendation for the drug risdiplam, marketed under the name Evrysdi by Roche, to include patients over the age of 25. This significant development was decided during the council’s meeting today and represents a major advancement in the availability of treatment options for individuals suffering from this debilitating neuromuscular disorder.
Previously, Medicinrådet’s recommendation for risdiplam was limited to children, adolescents, and adults up to the age of 25, based on the available clinical evidence supporting the drug’s effectiveness primarily in younger populations. However, a newly negotiated pricing agreement with Roche has made it possible to expand the treatment recommendation to all age groups, including adults over 25 years old, who were previously excluded due to concerns about the drug’s efficacy and cost.
The new pricing agreement was a critical factor in the council’s decision to extend the recommendation. The agreement includes a tiered discount structure that adjusts the cost of risdiplam according to the varying levels of clinical evidence supporting its effectiveness across different age groups. The strongest evidence of benefit is observed in young children under the age of six, where the drug has been shown to significantly improve motor function and potentially alter the course of the disease.
The evidence becomes progressively weaker for older children and young adults, and it is particularly sparse for adults over the age of 25. This pricing model has been carefully designed to ensure that the cost of the drug reflects its demonstrated benefits, making the treatment more accessible while also protecting hospital budgets from unexpected financial strain.
Medicinrådet Expands Spinal Muscular Atrophy Treatment to All Ages, Balancing Cost and Efficacy Concerns with New Pricing Agreement
“We had significant concerns about extending the recommendation to the oldest group of patients, particularly given the limited evidence of efficacy in this population and the high cost of treatment,” said Birgitte Klindt Poulsen, Vice Chair of Medicinrådet. “However, we are pleased that Roche has presented an agreement where there is a more appropriate balance between price and expected benefit, ensuring that the overall financial impact on hospitals remains manageable. This is an important consideration in ensuring that we can offer this treatment to more patients without compromising the sustainability of our healthcare system.”
The extension of the recommendation means that patients of all ages with SMA who meet specific initiation criteria, as outlined in Medicinrådet’s drug recommendation and treatment guidelines, can now be considered for treatment with risdiplam. These criteria are designed to ensure that the treatment is provided to those who are most likely to benefit from it. Despite the broader recommendation, Medicinrådet maintains that treatment should be discontinued if it does not show effectiveness in individual patients. The precise criteria for starting and stopping treatment are detailed in Medicinrådet’s official drug recommendation and treatment guidelines for spinal muscular atrophy.
Expansion of Risdiplam Use Marks Major Progress in Spinal Muscular Atrophy Treatment, Ensuring Broader Access Across All Ages
The decision to expand the use of risdiplam to older adults is seen as a significant step forward in the treatment of spinal muscular atrophy, a genetic disorder that leads to progressive muscle wasting and weakness. SMA primarily affects motor neurons in the spinal cord, leading to severe physical disability and, in the most severe cases, life-threatening complications. The availability of risdiplam has already transformed the treatment landscape for younger patients, offering a non-invasive, oral therapy that can be taken at home, in contrast to other SMA treatments that require invasive procedures or regular hospital visits.
By expanding access to risdiplam, Medicinrådet is aiming to ensure that more patients with spinal muscular atrophy, regardless of age, can benefit from the advances in treatment that have become available in recent years. The council’s decision underscores the importance of making evidence-based, cost-effective treatments accessible to all patients who need them, while also considering the broader implications for the healthcare system.
Expansion of SMA Treatment Praised by Advocacy Groups, Highlights Need for Sustainable Access to Innovative Therapies
This development has been welcomed by patient advocacy groups and healthcare professionals alike, who have long called for more inclusive treatment options for spinal muscular atrophy. While the extension of the recommendation represents a significant achievement, it also highlights the ongoing challenges in ensuring that new and expensive therapies are made available in a way that is both equitable and sustainable.
Looking ahead, the success of this expanded recommendation will depend on careful monitoring of the treatment’s outcomes in older patients and continued collaboration between healthcare providers, patients, and pharmaceutical companies. Medicinrådet’s decision reflects a balanced approach that prioritizes patient care while safeguarding the financial integrity of the healthcare system. As the G-BA moves forward with implementing the provisions of the Healthy Heart Law, it will continue to play a crucial role in shaping the future of cardiovascular care in Germany, ensuring that patients receive care that is both scientifically sound and aligned with their best interests.
The expansion of risdiplam’s availability marks an important milestone in the fight against spinal muscular atrophy and sets a precedent for future decisions regarding the accessibility of innovative treatments for rare and serious diseases.
Resource: Danish Medicines Council, August 28, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
